Details of the Drug

General Information of Drug (ID: DMOL54H)

Drug Name
Clopidogrel
Synonyms
clopidogrel; 113665-84-2; (S)-Clopidogrel; Plavix; Clopidogrel [INN:BAN]; (+)-(S)-Clopidogrel; (+)-Clopidogrel; UNII-A74586SNO7; HSDB 7430; CLOPIDOGREL SULFATE; CHEBI:37941; GKTWGGQPFAXNFI-HNNXBMFYSA-N; A74586SNO7; CPD000550475; Zyllt; Clopidogrel (TN); SR-25990C; Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Clopidogrelum; Thrombo; Clopidogrel BMS; Clopidogrel Hexal; Clopidogrel Acino; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; PM-103; Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Thrombosis DB61-GB90 Approved [1], [2], [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 321.8
Topological Polar Surface Area (xlogp) 3.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 23.65 mL/min/kg [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.06 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.3168 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.01 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.05078 mg/mL [4]
Chemical Identifiers
Formula
C16H16ClNO2S
IUPAC Name
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
Canonical SMILES
COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
InChI
InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
InChIKey
GKTWGGQPFAXNFI-HNNXBMFYSA-N
Cross-matching ID
PubChem CID
60606
ChEBI ID
CHEBI:37941
CAS Number
113665-84-2
DrugBank ID
DB00758
TTD ID
D0N0TZ
VARIDT ID
DR00245
INTEDE ID
DR0355
ACDINA ID
D00142

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2Y purinoceptor 12 (P2RY12) TTZ1DT0 P2Y12_HUMAN Antagonist [7], [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clopidogrel
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Clopidogrel and Apixaban. Thrombosis [DB61-GB90] [78]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Clopidogrel and Brilinta. Thrombosis [DB61-GB90] [78]
Coadministration of a Drug Treating the Disease Different from Clopidogrel (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Major Decreased metabolism of Clopidogrel caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [79]
Pioglitazone DMKJ485 Major Decreased metabolism of Clopidogrel caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [80]
Oliceridine DM6MDCF Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Oliceridine. Acute pain [MG31] [81]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Clopidogrel caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [82]
Rabeprazole DMMZXIW Major Decreased metabolism of Clopidogrel caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [83]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Clopidogrel caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [82]
Pexidartinib DMS2J0Z Moderate Decreased metabolism of Clopidogrel caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [83]
Loperamide DMOJZQ9 Major Decreased metabolism of Clopidogrel caused by Loperamide mediated inhibition of CYP450 enzyme. Bowel habit change [ME05] [84]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Clopidogrel caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [85]
Tucatinib DMBESUA Major Decreased metabolism of Clopidogrel caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [86]
Letrozole DMH07Y3 Moderate Decreased metabolism of Clopidogrel caused by Letrozole mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [83]
Atorvastatin DMF28YC Moderate Increased plasma concentrations of Clopidogrel and Atorvastatin due to competitive inhibition of the same metabolic pathway. Cardiovascular disease [BA00-BE2Z] [82]
Dihydrocodeine DMB0FWL Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Dihydrocodeine. Chronic pain [MG30] [87]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Clopidogrel and Levomilnacipran. Chronic pain [MG30] [88]
Anisindione DM2C48U Major Increased risk of bleeding by the combination of Clopidogrel and Anisindione. Coagulation defect [3B10] [89]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Clopidogrel and Regorafenib. Colorectal cancer [2B91] [78]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Clopidogrel and Intedanib. Colorectal cancer [2B91] [90]
Alfentanil DMVO0UB Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Alfentanil. Corneal disease [9A76-9A78] [81]
Remifentanil DMZTXCH Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Remifentanil. Corneal disease [9A76-9A78] [81]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Clopidogrel and Ardeparin. Coronary thrombosis [BA43] [91]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Clopidogrel caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [83]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Clopidogrel and Danaparoid. Deep vein thrombosis [BD71] [91]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Clopidogrel and Rivaroxaban. Deep vein thrombosis [BD71] [92]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Clopidogrel and Sertraline. Depression [6A70-6A7Z] [88]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Clopidogrel and Vilazodone. Depression [6A70-6A7Z] [88]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Clopidogrel and Vortioxetine. Depression [6A70-6A7Z] [88]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Clopidogrel and Milnacipran. Depression [6A70-6A7Z] [88]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Clopidogrel and Escitalopram. Depression [6A70-6A7Z] [88]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Clopidogrel and Desvenlafaxine. Depression [6A70-6A7Z] [88]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Clopidogrel and Clomipramine. Depression [6A70-6A7Z] [88]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Clopidogrel and Heme. Discovery agent [N.A.] [93]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Clopidogrel and Apigenin. Discovery agent [N.A.] [94]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Clopidogrel and PMID28870136-Compound-49. Discovery agent [N.A.] [79]
Felbamate DM1V5ZS Moderate Decreased metabolism of Clopidogrel caused by Felbamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Clopidogrel caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Cenobamate DMGOVHA Moderate Decreased metabolism of Clopidogrel caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Fosphenytoin DMOX3LB Minor Decreased metabolism of Clopidogrel caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [95]
Brivaracetam DMSEPK8 Moderate Decreased metabolism of Clopidogrel caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Eslicarbazepine DMZREFQ Moderate Decreased metabolism of Clopidogrel caused by Eslicarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Clopidogrel and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [96]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Clopidogrel caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [83]
Dexlansoprazole DM1DBV5 Minor Increased plasma concentrations of Clopidogrel and Dexlansoprazole due to competitive inhibition of the same metabolic pathway. Gastro-oesophageal reflux disease [DA22] [97]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Clopidogrel and Avapritinib. Gastrointestinal stromal tumour [2B5B] [78]
Rifampin DMA8J1G Moderate Increased metabolism of Clopidogrel caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [87]
Cobicistat DM6L4H2 Major Decreased metabolism of Clopidogrel caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Clopidogrel and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [98]
Etravirine DMGV8QU Moderate Decreased metabolism of Clopidogrel caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Fluvastatin DM4MDJY Minor Decreased metabolism of Clopidogrel caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [95]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Clopidogrel caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [83]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Clopidogrel caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [99]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Clopidogrel caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [87]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Clopidogrel and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [100]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Clopidogrel and Acalabrutinib. Mature B-cell lymphoma [2A85] [101]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Clopidogrel and Ibrutinib. Mature B-cell lymphoma [2A85] [81]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Clopidogrel and Ponatinib. Mature B-cell lymphoma [2A85] [102]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Clopidogrel and Panobinostat. Multiple myeloma [2A83] [87]
Ozanimod DMT6AM2 Major Decreased metabolism of Clopidogrel caused by Ozanimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [87]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Clopidogrel caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [83]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Clopidogrel and Dasatinib. Myeloproliferative neoplasm [2A20] [103]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Clopidogrel and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [104]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Clopidogrel and Prasugrel. Myocardial infarction [BA41-BA43] [78]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Clopidogrel and Tirofiban. Myocardial infarction [BA41-BA43] [105]
Bupropion DM5PCS7 Moderate Decreased metabolism of Clopidogrel caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [87]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Clopidogrel and Sibutramine. Obesity [5B80-5B81] [88]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Clopidogrel and Dexfenfluramine. Obesity [5B80-5B81] [88]
Levomethadyl Acetate DM06HG5 Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Levomethadyl Acetate. Opioid use disorder [6C43] [87]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Clopidogrel and Nepafenac. Osteoarthritis [FA00-FA05] [96]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Clopidogrel and MK-4827. Ovarian cancer [2C73] [78]
Oxymorphone DM65AGJ Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Oxymorphone. Pain [MG30-MG3Z] [81]
Levorphanol DMGS80V Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Levorphanol. Pain [MG30-MG3Z] [81]
Dezocine DMJDB0Y Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Dezocine. Pain [MG30-MG3Z] [81]
Nalbuphine DMOSQGU Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Nalbuphine. Pain [MG30-MG3Z] [81]
Buprenorphine DMPRI8G Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Buprenorphine. Pain [MG30-MG3Z] [81]
Hydrocodone DMQ2JO5 Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Hydrocodone. Pain [MG30-MG3Z] [81]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Clopidogrel and Bromfenac. Postoperative inflammation [1A00-CA43] [96]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Clopidogrel caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [83]
Enzalutamide DMGL19D Moderate Decreased metabolism of Clopidogrel caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [106]
Selexipag DMAHSU0 Moderate Decreased metabolism of Clopidogrel caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [87]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Clopidogrel and Epoprostenol. Pulmonary hypertension [BB01] [107]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Clopidogrel and Iloprost. Pulmonary hypertension [BB01] [107]
Fentanyl DM8WAHT Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Fentanyl. Sensation disturbance [MB40] [81]
Armodafinil DMGB035 Moderate Decreased metabolism of Clopidogrel caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [83]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Clopidogrel and Curcumin. Solid tumour/cancer [2A00-2F9Z] [108]
Taxol DMUOT9V Moderate Decreased metabolism of Clopidogrel caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [109]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Clopidogrel and Caplacizumab. Thrombocytopenia [3B64] [87]
Tolbutamide DM02AWV Minor Decreased metabolism of Clopidogrel caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [95]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Clopidogrel and Betrixaban. Venous thromboembolism [BD72] [110]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Clopidogrel caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [111]
⏷ Show the Full List of 88 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Caprylic acid E00017 379 Emulsifying agent; Flavoring agent; Surfactant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glyceryl dibehenate E00537 22477175 Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Zinc stearate E00209 11178 lubricant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Trihydroxystearin E00317 25100 Emollient; Emulsifying agent; Solvent; Surfactant; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clopidogrel 75 mg tablet 75 mg Oral Tablet Oral
Clopidogrel 300 mg tablet 300 mg Oral Tablet Oral
Clopidogrel Bisulfate 75mg/300mg tablet 75mg/300mg Tablet Oral
Clopidogrel Bisulfate 75mg tablet 75mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7150).
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029432)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328).
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
8 Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
9 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
10 Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
11 Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
12 Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66.
13 Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
24 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
25 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
26 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
27 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
28 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
30 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
31 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
32 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
33 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
34 Drug Interactions Flockhart Table
35 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
36 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
37 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
38 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
39 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
40 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
41 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
42 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
43 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
44 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
45 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
46 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
47 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
48 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
49 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
50 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
51 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
52 Drugs that may have potential CYP2B6 interactions.
53 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
54 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
55 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
56 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
57 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
58 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
59 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
60 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
61 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
62 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
63 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
64 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
65 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
66 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
67 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
68 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
69 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
70 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
71 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
72 Clinical pipeline report, company report or official report of AstraZeneca (2009).
73 Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56.
74 Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8.
75 Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
76 Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
77 Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005 Sep;94(3):593-8.
78 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
79 Canadian Pharmacists Association.
80 Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT "Clopidogrel Markedly Increases the Plasma Concentrations of the CYP2C8 Substrate Pioglitazone." Drug Metab Dispos (2016):. [PMID: 27260150]
81 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
82 Clarke TA, Waskell LA "The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin." Drug Metab Dispos 31 (2003): 53-9. [PMID: 12485953]
83 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
84 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
85 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
87 Cerner Multum, Inc. "Australian Product Information.".
88 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
89 Anand S, Yusuf S, Xie C, et al. "Oral anticoagulant and antiplatelet therapy and peripheral arterial disease." N Engl J Med 357 (2007): 217-27. [PMID: 17634457]
90 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
91 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
92 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
93 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
94 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
95 Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
96 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
97 Product Information. Dexilant (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
98 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
99 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
100 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
101 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
102 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
103 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
104 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
105 Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A." Clin Pharmacol Ther 67 (2000): 305-13. [PMID: 10741635]
106 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
107 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
108 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
109 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
110 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.
111 Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T "Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions." Br J Clin Pharmacol 49 (2000): 244-53. [PMID: 10718780]